mj wowowin Flag football scours nation with talent camps to uncover next wave of starsOne of the interesting facts about Scott Morrison’s period as prime minister is that he managed to squander public approval twice. The second came via a long, protracted slide through most of the pandemic. But in fact his popularity had sunk as low – and much, much faster, at least in Newspoll – just a few months after his 2019 election victory. The main event involved was that summer’s bushfires. His trip to Hawaii is the symbol of that failure, but the actual problems were long and drawn-out. There was the slowness to act and the failure to meet with emergency leaders, the mangled handshakes, “I don’t hold a hose” and the sidestepping of the climate debate. Prime Minister Anthony Albanese and Opposition Leader Peter Dutton are neck and neck in opinion polls. Credit: Alex Ellinghausen The political ramifications of a natural disaster are the least important thing about it. I recount this because it’s always worth keeping in mind, in politics, how quickly things can change. Also: how dominant a crisis can be. Morrison’s disastrous summer, in fact, was only really rescued by the advent of another crisis – the early part of the pandemic, when his numbers soared – before that crisis, too, destroyed him. Recent weeks have seen at least two significant shifts, with another at least possible. For a long time, it seemed as though the Albanese government would get a rate cut – even two – before the election. As I wrote a few weeks back, this had the potential to act as tangible affirmation of its economic strategy , the other elements of which – wage growth, job creation – had been lining up nicely. Last week, Westpac joined NAB in predicting the next rate cut would come on May 20 – three days after the last possible date for the election. The government now has to hope voters’ moods improve without that rate cut. It’s possible. Essential poll last week found a small fall in people who say they’re struggling. There was a small but notable shift in one of the more interesting indicators: whether people believe the country is on the right track. It’s too early to spot a trend, and more people disagree than agree – but the “right direction” figure was (just) the highest it’s been since May 2023 . Illustration by Joe Benke Credit: The second change is the victory of Donald Trump. There are signs – like his retreat from the nomination of Matt Gaetz as attorney-general – that Trump’s term may be as bizarre as his first. One veteran observer suggested to me some time ago that a Trump victory may play into Albanese’s slow-and-steady approach: that in an era of messiness, boredom becomes appealing. At present, though, the opposite is the case. Last week, a Freshwater Strategy poll in the Australian Financial Review found 36 per cent of voters believed Albanese was best placed to deal with Trump – against 47 per cent who favoured Dutton. Finally, we should all hope this is a quiet season for natural disasters. Recent weeks have reminded us, this can’t be taken for granted. There have been bushfires in Queensland, the ABC reporting that amid the smoke last month Mount Isa was briefly “the most polluted city in the world”. There were evacuations in response to fires in Victoria (arson seems to have played a role in several of these). How bushfires might affect the political situation would depend, to a great extent, on the prime minister’s response. This close to a poll, major conclusions drawn would be about him personally. How Albanese handled the question of climate change would be significant. (That same Essential poll found only half of voters believe hotter summers are the result of climate change.) But what would also move into the spotlight would be the continuing climate change splits within the opposition. Here we come to another recent shift, one that is sharpening the political contest. At the beginning of this term, it seemed Peter Dutton wanted to oppose most things: he had not yet learnt the fine art of picking his battles. In recent months, he has avoided fights on some key issues: aged care, disabilities and social media. Even his apparently “bold” foray on nuclear energy, as I’ve argued before , is best understood in this context: wanting to avoid a battle, either within his party or with Labor, over whether climate change action is necessary. Yet Dutton has picked a very specific fight: he will oppose Labor’s bill to bring down international student numbers – even though he has long suggested that’s his aim too. As journalist Bernard Keane observed , this is a mirror of Donald Trump’s successful move to block an immigration bill to keep the problem alive. This is of a piece with Dutton’s earlier decisions to make Labor’s life difficult on immigration detention bills. Dutton has learnt to use the parliament to narrow the political contest to his preferred issues, with immigration top of the list. With that in mind, it will be interesting to see what happens when Labor finally announces its universal childcare policy. Labor is hoping for significant political credit. But what if Dutton simply says he agrees? Meanwhile, there are some fights the nation should be having but isn’t. Bill Shorten, farewelling parliament last week, pointed out “our system still taxes property preferentially and lightly – and income heavily”. Anthony Whealy, chair of the Centre for Public Integrity, pointed out that the government and opposition seem to have reached an agreement, funnily enough, on donations changes that don’t do enough about money in politics while also giving the major parties advantages over independents. As Albanese told Sky News, “we’ve already chosen our slogan as you know, ‘building Australia’s future’.” Dutton seems to have chosen his issues, too. Given how much has changed in the past few weeks, and how much might still change in the months before polling day, both men would be wise to keep their options open. Sean Kelly is author of The Game: A Portrait of Scott Morrison , a regular columnist and a former adviser to Julia Gillard and Kevin Rudd.Smith scores 18 in Bellarmine's 80-68 win against Bowling GreenNone

None

TORONTO — Everything changed for Kia Nurse when she tore her anterior cruciate ligament in the 2021 WNBA playoffs. The basketball star from Hamilton was locked in as starter for a team in the semifinals. She’d been selected as an all-star just two years prior. But in one awkward fall three years ago, she was plunged into the depths of surgery and rehab. Nurse would miss the entire 2022 season due to the injury. She signed with the Seattle Storm for the 2023 campaign before a trade landed her with the Los Angeles Sparks last season. Meanwhile, Nurse represented Canada at the Paris Olympics in August, but she struggled as the team failed to reach the knockout round for the second straight time. The common thread throughout Nurse’s recent basketball journey? She just hasn’t quite felt like herself. “I still love basketball with all of my heart, and it's my favourite thing that I get to do. And I'm so privileged to be able to say that I get to do it as a job,” Nurse said. "But the last two years for me have been just really rocky, up and down.” Nurse, 28, will become a WNBA free agent as of Feb. 1. For now, she’s continuing her Raptors broadcast work with TSN and, on Monday, announced a new playing gig. In February, Nurse will join fellow WNBAers Alysha Clark and Sydney Colson among 37 others for Athletes Unlimited’s third basketball season in Nashville. Athletes Unlimited was founded as a women’s professional softball league in 2020 before expanding to basketball, volleyball and lacrosse. Its 24-game hoops campaign switches teams weekly and concludes by crowning a season-long individual champion. Players earn points through a fantasy-style system that rewards team successes like wins as well as individual accomplishments from made three-pointers to steals to drawn fouls. Outside of the unique scoring system, the game looks like traditional basketball — a major appeal to Nurse as she attempts to tap back into her roots. “I am not proud of my performance at the Olympics and not necessarily proud of how I’ve been playing over the last two years. I just have goals of finding my true love of the game and kind of coming back and being stronger physically, being more fit and just ultimately having a good year,” Nurse said. When Nurse’s career began in 2018, many WNBA players would ply their trade overseas during the off-season as a way of staying in shape and making additional money. But over the past half-decade — and perhaps expedited by Brittney Griner’s 2022 detainment in Russia — more options have emerged stateside, including Athletes Unlimited. “The (WNBA) now has a lot of the teams that have practice facilities, so they have full-time player development, practice-facility access and that's a big piece as well. But now ultimately we have these leagues at home like AU,” Nurse said. Athletes Unlimited will not be the only professional women’s basketball operation in North America this winter. A three-on-three league called Unrivaled, founded by WNBA stars Napheesa Collier and Breanna Stewart, will tip off in January in Miami. Nurse said Unrivaled was an option for her, but she preferred Athletes Unlimited. “I wanted a place where I'm happy with basketball again, really happy with myself and how I'm playing and a having a little more confidence boost from what I've had over these last two years. And I feel like AU, for me, that five-on-five setting was a big piece of it,” Nurse said. The timing of the Athletes Unlimited schedule — deep enough into the WNBA off-season but with enough leeway to fine tune things before the 2025 campaign begins — also stood out to Nurse. Ahead of AU, Nurse said she moved her training from Toronto to Hamilton, where she could stay closer to home and avoid the long highway drives. And following two seasons in which Nurse’s WNBA teams suffered a combined 61 losses, she’s hoping to find a landing spot in free agency with a winning franchise. “I want to ... have an opportunity make a deep playoff run, be kind of like an X-Factor player, somebody who can go out there, be a three-and-D player, can help make winning plays,” she said. Nurse said she and fellow WNBA veteran Bridget Carleton have discussed what went wrong in Paris and how it can be fixed ahead of Los Angeles 2028. Management changes have already occurred with the retirement of GM Denise Dignard and a mutual parting with head coach Victor Lapena. The national team recently met up in Toronto for an informal training camp where Nurse and Carleton aimed to lay the groundwork for the culture they hope to create over the next four years. “Getting back to the basics and just enjoying playing for Canada Basketball, but also creating a really strong, bonded culture where everybody does what they need to do for our team to win," she said. "We understand our roles (and) we understand the commitment piece of it because now there's so much going on and people are all over the place." This report by The Canadian Press was first published Nov. 22, 2024. Myles Dichter, The Canadian PressFrench PM Bayrou defends choices to lead country out of 'difficult situation'Stock market today: Tech stocks and AI pull Wall Street to more recordsBC Quashes Controversial Bill Limiting Public Drug Use

Bison football adds Omaha three-star defensive end prospect Alijah WaynePeripheral T Cell Lymphomas Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharma 12-23-2024 11:04 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Peripheral T Cell Lymphomas Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Peripheral T Cell Lymphomas Pipeline Insight, 2024 [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral T Cell Lymphomas Market. Some of the key takeaways from the Peripheral T Cell Lymphomas Pipeline Report: * Companies across the globe are diligently working toward developing novel Peripheral T Cell Lymphomas treatment therapies with a considerable amount of success over the years. * Peripheral T Cell Lymphomas companies working in the treatment market are HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others, are developing therapies for the Peripheral T Cell Lymphomas treatment * Emerging Peripheral T Cell Lymphomas therapies in the different phases of clinical trials are- HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others are expected to have a significant impact on the Peripheral T Cell Lymphomas market in the coming years. * In December 2024, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced new data showcasing significant improvements in quality of life for patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. The findings were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. * In December 2024, Secura Bio, Inc. (Secura Bio), an integrated pharmaceutical company focused on the global development and commercialization of effective oncology therapies, presented two posters at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The first poster showcased new data from the Company's Phase 2 PRIMO trial of duvelisib for treating relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL), while the second poster outlined the clinical design for the planned Phase 3 randomized trial of duvelisib in R/R nodal T-follicular helper cell lymphoma (TERZO Trademark ). Peripheral T Cell Lymphomas Overview Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive blood cancers that develop in T-cells, a type of white blood cell involved in immune function. Unlike other types of lymphoma, PTCL originates outside the bone marrow, typically in lymph nodes, spleen, or other tissues. Symptoms may include swollen lymph nodes, fever, weight loss, night sweats, and skin rashes. PTCL is rare and often more difficult to treat compared to other lymphomas. Treatment options may include chemotherapy, immunotherapy, stem cell transplants, and targeted therapies, depending on the specific subtype and stage of the disease. Get a Free Sample PDF Report to know more about Peripheral T Cell Lymphomas Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight [ https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Emerging Peripheral T Cell Lymphomas Drugs Under Different Phases of Clinical Development Include: * HBI-8000: HUYA Bioscience International * AT-104: Applied Therapeutics * Auto 5: Autolus * AK 104: Akeso Biopharma * Tolinapant: Astex Pharmaceuticals * Duvelisib: Secura Bio * Lacutamab: Innate Pharma * AZD 4205: Dizal Pharmaceutical * Mitoxantrone liposomal: CSPC ZhongQi Pharmaceutical Technology Peripheral T Cell Lymphomas Route of Administration Peripheral T Cell Lymphomas pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as * Subcutaneous * Intravenous * Oral * Intramuscular * Intra-tumoral * Molecule Type Peripheral T Cell Lymphomas Molecule Type Peripheral T Cell Lymphomas Products have been categorized under various Molecule types, such as * Monoclonal antibodies * Immunoglobulins * Small molecules * Pyrimidines * Proteins and Peptides * Product Type Peripheral T Cell Lymphomas Pipeline Therapeutics Assessment * Peripheral T Cell Lymphomas Assessment by Product Type * Peripheral T Cell Lymphomas By Stage and Product Type * Peripheral T Cell Lymphomas Assessment by Route of Administration * Peripheral T Cell Lymphomas By Stage and Route of Administration * Peripheral T Cell Lymphomas Assessment by Molecule Type * Peripheral T Cell Lymphomas by Stage and Molecule Type DelveInsight's Peripheral T Cell Lymphomas Report covers around 40+ products under different phases of clinical development like * Late-stage products (Phase III) * Mid-stage products (Phase II) * Early-stage product (Phase I) * Pre-clinical and Discovery stage candidates * Discontinued & Inactive candidates * Route of Administration Further Peripheral T Cell Lymphomas product details are provided in the report. Download the Peripheral T Cell Lymphomas pipeline report to learn more about the emerging Peripheral T Cell Lymphomas therapies [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Some of the key companies in the Peripheral T Cell Lymphomas Therapeutics Market include: Key companies developing therapies for Peripheral T Cell Lymphomas are - Celleron Therapeutics, Myeloid Therapeutics, Astex Pharmaceuticals, Citius Pharmaceuticals, Innate Pharma, Secura Bio, Genor Biopharma Co., Ltd., CerRx, Inc., Dizal Pharmaceuticals, Kura Oncology, Inc., Viracta Therapeutics, Autolus Therapeutics, Affimed Therapeutics, C4 Therapeutics, Kymera Therapeutics, Daiichi Sankyo, SciTech Development LLC, Sorrento Therapeutics, Bristol-Myers Squibb, Shanghai Yingli Pharmaceutical, Ono Pharmaceutical, and others. Peripheral T Cell Lymphomas Pipeline Analysis: The Peripheral T Cell Lymphomas pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T Cell Lymphomas with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T Cell Lymphomas Treatment. * Peripheral T Cell Lymphomas key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Peripheral T Cell Lymphomas Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T Cell Lymphomas market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Peripheral T Cell Lymphomas drugs and therapies [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Peripheral T Cell Lymphomas Pipeline Market Drivers * Increase in incidences of PTCL, rising investment for the development of advanced technologies, surge in government initiatives to promote research and awareness about the disease are some of the important factors that are fueling the Peripheral T Cell Lymphomas Market. Peripheral T Cell Lymphomas Pipeline Market Barriers * However, high cost associated with the treatment, lack of skilled professionals for early diagnosis of the disease and other factors are creating obstacles in the Peripheral T Cell Lymphomas Market growth. Scope of Peripheral T Cell Lymphomas Pipeline Drug Insight * Coverage: Global * Key Peripheral T Cell Lymphomas Companies: HUYA Bioscience International, Applied Therapeutics, Autolus, Akeso Biopharma, Astex Pharmaceuticals, Secura Bio, Innate Pharma, Dizal Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, and others * Key Peripheral T Cell Lymphomas Therapies: HBI-8000, AT-104, Auto 5, AK 104, Tolinapant, Duvelisib, Lacutamab, AZD 4205, Mitoxantrone liposomal, and others * Peripheral T Cell Lymphomas Therapeutic Assessment: Peripheral T Cell Lymphomas current marketed and Peripheral T Cell Lymphomas emerging therapies * Peripheral T Cell Lymphomas Market Dynamics: Peripheral T Cell Lymphomas market drivers and Peripheral T Cell Lymphomas market barriers Request for Sample PDF Report for Peripheral T Cell Lymphomas Pipeline Assessment and clinical trials [ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Table of Contents 1. Peripheral T Cell Lymphomas Report Introduction 2. Peripheral T Cell Lymphomas Executive Summary 3. Peripheral T Cell Lymphomas Overview 4. Peripheral T Cell Lymphomas- Analytical Perspective In-depth Commercial Assessment 5. Peripheral T Cell Lymphomas Pipeline Therapeutics 6. Peripheral T Cell Lymphomas Late Stage Products (Phase II/III) 7. Peripheral T Cell Lymphomas Mid Stage Products (Phase II) 8. Peripheral T Cell Lymphomas Early Stage Products (Phase I) 9. Peripheral T Cell Lymphomas Preclinical Stage Products 10. Peripheral T Cell Lymphomas Therapeutics Assessment 11. Peripheral T Cell Lymphomas Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Peripheral T Cell Lymphomas Key Companies 14. Peripheral T Cell Lymphomas Key Products 15. Peripheral T Cell Lymphomas Unmet Needs 16 . Peripheral T Cell Lymphomas Market Drivers and Barriers 17. Peripheral T Cell Lymphomas Future Perspectives and Conclusion 18. Peripheral T Cell Lymphomas Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=peripheral-t-cell-lymphomas-pipeline-2024-clinical-trials-assessment-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-celleron-therapeutics-myeloid-therapeutics-astex-pharma ] Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.

Mike McCarthy Responds To What Jerry Jones Said About His ContractHuge Australian crocodile made famous by cameo role in Crocodile Dundee dies

From Boeing to bots, rebrands and the Budget – test your city wits with our fiendish festive financial quizIdaho has 85 mountain ranges and subranges. Man with Pocatello roots summited the highest peak in each

We needed it – Pep Guardiola relieved to end Man City’s winless runThrivent Financial for Lutherans decreased its position in Eversource Energy ( NYSE:ES – Free Report ) by 24.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,477 shares of the utilities provider’s stock after selling 22,631 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Eversource Energy were worth $4,797,000 as of its most recent SEC filing. Other institutional investors also recently modified their holdings of the company. Lynx Investment Advisory acquired a new position in Eversource Energy during the 2nd quarter worth $25,000. Ashton Thomas Securities LLC bought a new position in shares of Eversource Energy in the third quarter worth about $32,000. UMB Bank n.a. lifted its position in shares of Eversource Energy by 62.9% during the 3rd quarter. UMB Bank n.a. now owns 513 shares of the utilities provider’s stock worth $35,000 after purchasing an additional 198 shares during the last quarter. Pathway Financial Advisers LLC bought a new stake in Eversource Energy during the 1st quarter valued at approximately $43,000. Finally, MFA Wealth Advisors LLC bought a new stake in Eversource Energy during the 3rd quarter valued at approximately $48,000. Institutional investors own 79.99% of the company’s stock. Analysts Set New Price Targets ES has been the subject of several research reports. Bank of America increased their price objective on Eversource Energy from $67.00 to $68.00 and gave the company a “neutral” rating in a research report on Thursday, August 29th. StockNews.com upgraded shares of Eversource Energy from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. Scotiabank raised their price target on shares of Eversource Energy from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Tuesday, August 20th. Barclays upped their price objective on shares of Eversource Energy from $69.00 to $72.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 15th. Finally, Wells Fargo & Company boosted their price target on Eversource Energy from $72.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $70.46. Eversource Energy Stock Up 1.0 % Shares of ES opened at $63.38 on Friday. The company has a market capitalization of $23.22 billion, a P/E ratio of -40.37, a PEG ratio of 2.51 and a beta of 0.61. Eversource Energy has a one year low of $52.09 and a one year high of $69.01. The business’s 50 day simple moving average is $64.68 and its 200-day simple moving average is $62.92. The company has a debt-to-equity ratio of 1.73, a current ratio of 0.86 and a quick ratio of 0.76. Eversource Energy ( NYSE:ES – Get Free Report ) last posted its quarterly earnings data on Monday, November 4th. The utilities provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.05. The company had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.06 billion. Eversource Energy had a positive return on equity of 10.90% and a negative net margin of 4.73%. The business’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.97 earnings per share. As a group, sell-side analysts predict that Eversource Energy will post 4.56 EPS for the current fiscal year. Eversource Energy Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 23rd were issued a dividend of $0.715 per share. This represents a $2.86 dividend on an annualized basis and a yield of 4.51%. The ex-dividend date was Monday, September 23rd. Eversource Energy’s dividend payout ratio is currently -182.17%. Eversource Energy Company Profile ( Free Report ) Eversource Energy, a public utility holding company, engages in the energy delivery business. The company operates through Electric Distribution, Electric Transmission, Natural Gas Distribution, and Water Distribution segments. It is involved in the transmission and distribution of electricity; solar power facilities; and distribution of natural gas. Further Reading Receive News & Ratings for Eversource Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eversource Energy and related companies with MarketBeat.com's FREE daily email newsletter .Surveillance tech advances by Biden could aid in Trump’s promised crackdown on immigration

Northwestern women blank Saint Joseph’s to win 2nd national field hockey titlePep Guardiola spoke of his relief after Manchester City finally got back to winning ways with a comfortable 3-0 defeat of Nottingham Forest on Wednesday. The champions had descended into crisis after a run of seven games without a win – six of which were defeats and the other an embarrassing 3-3 draw after leading 3-0. Four of those losses had come in the Premier League, heavily damaging their chances of claiming a fifth successive title, but they appeared to turn the corner by sweeping Forest aside at the Etihad Stadium. “We needed it,” said City manager Guardiola. “The club, the players, everyone needed to win. A good night's work 🫡 Thank you for backing us all the way, City fans 🩵 pic.twitter.com/UOcKm0Y6Ry — Manchester City (@ManCity) December 4, 2024 “But it is just one game and in three days we are at Selhurst Park, where it has always been difficult. “We played good. We still conceded some transitions and missed some easy things and lost some passes that you have to avoid, but in general, the most important thing was to break this routine of not winning games and we won it.” Kevin De Bruyne, making his first start since September after overcoming a pelvic injury, made a huge difference to a side that appeared rejuvenated. His powerful header was turned in by Bernardo Silva for the opening goal and the Belgian followed up with a powerful strike to make it 2-0. The 33-year-old is out of contract at the end of the season but it was a strong riposte to recent suggestions of a rift with Guardiola. A sweet strike 💥 ⚡️ #HighSpeedMoments | @eAndGroup pic.twitter.com/WJOkfKo2zr — Manchester City (@ManCity) December 4, 2024 “I’m so happy for him,” said Guardiola of De Bruyne’s telling contribution. “Last season he was many months injured and this season as well. “I’m so happy he’s back. He fought a lot, he’s worked and he’s back with his physicality. The minutes he played in Anfield were really good and today he played 75 fantastic minutes.” Jeremy Doku wrapped up a pleasing win when he finished a rapid counter-attack just before the hour but there was still a downside for City with injuries to defenders Nathan Ake and Manuel Akanji. Guardiola said: “For Nathan it doesn’t look good and Manu has struggled a lot over the last two months. We will see. “Phil (Foden) has bronchitis but when he doesn’t have fever he will be ready.” Despite City’s dominance, Forest did have some bright moments and manager Nuno Espirito Santo was not downbeat. He said: “When you lose 3-0 and you say it was a good performance maybe people don’t understand, but I will not say that was a bad performance. “There are positive things for us in the game. Of course there are a lot of bad things, mistakes, but we had chances. “We didn’t achieve but I think we come out proud of ourselves because we tried. For sure, this game will allow us to grow.”

Suspended soccer coach Bev Priestman has broken her silence, saying she hopes something positive comes out of the ongoing Canadian drone-spying scandal. “I hope out of a really tough situation, this is a turning point for our game,” she wrote in an Instagram post via her verified account. “There has been a standard and precedent set now, irrespective of gender, tournament or associated revenues that will hopefully clean up our game.” She did not address her role in the affair in the six-paragraph post. Priestman, assistant coach Jasmine Mander and analyst Joey Lombardi are all serving one-year FIFA bans for their role in the scandal, which saw the Canada women’s team use a drone to spy on two New Zealand training sessions at the Olympics. Canada Soccer says the three won’t be back in the wake of the recent independent report into the scandal. Lombardi is already gone, having resigned his position after the Olympics. “The findings of the independent investigator reveal that the incident itself was a symptom of a difficult and unacceptable past culture within the national teams,” Canada Soccer chief executive officer and general secretary Kevin Blue and president and board chair Peter Augruso said in a statement when the report was released earlier this month. Canada Soccer continues to investigate the roots of the spying scandal and has initiated a disciplinary process against former men’s and women’s coach John Herdman, currently coach of Toronto FC. The governing body has said it “has initiated a proceeding with respect to Mr. Herdman under its Disciplinary Code.” Herdman did not speak to Sonia Regenbogen, who wrote the report. Priestman signed a new contract in January that runs through the 2027 FIFA Women’s World Cup. The 38-year-old Priestman took over the Canadian women on Nov. 1, 2020, and was initially appointed “through the next quadrennial.” She had been working on a rolling contract — until the new deal. “It has and will continue to take some time to process, heal, find the right words and step back into a public setting but I felt I should say something irrespective of ongoing circumstances,” Priestman wrote. In addition to the suspensions, FIFA docked the Canadian women six points in the group stage at the Olympics and fined Canada Soccer 200,000 Swiss francs ($312,815). Despite that, defending champion Canada still managed to make the knockout round before losing a penalty shootout to Germany in the quarterfinals. “I know that amazing group was ready to reach the top again this summer, but in many ways what they did was even more special under such difficult circumstances,” Priestman wrote. She also thanked those who had reached out to her. “You continue to help me through some dark days,” she said. Canadian under-20 coach Cindy Tye has been named interim coach for the sixth-ranked Canadians’ upcoming friendlies in Spain against Iceland and South Korea.Thrivent Financial for Lutherans Sells 22,631 Shares of Eversource Energy (NYSE:ES)AP Business SummaryBrief at 5:20 p.m. EST

LOS ANGELES (AP) — Defending national champion South Carolina women defeated by UCLA 77-62 for their first loss since the 2023 Final Four.